Dana L. Johnson

发表

An antagonist peptide–EPO receptor complex suggests that receptor dimerization is not sufficient for activation

Wen He, Enrico A. Stura, Ian A. Wilson, 1998, Nature Structural Biology.

Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin

Ronald W. Barrett, William J. Dower, R. Barrett, 1996, Science.

Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å

Enrico A. Stura, Ian A. Wilson, William J. Dower, 1996, Science.

1,2,3,4-Tetrahydroquinoline-containing αvβ3 integrin antagonists with enhanced oral bioavailability

G. Leo, Dana L. Johnson, R. Kawahama, 2004 .

Identification of a Critical Ligand Binding Determinant of the Human Erythropoietin Receptor

R. H. Gruninger, L. Jolliffe, S. Middleton, 1996, The Journal of Biological Chemistry.

Methode permettant de detecter des modulateurs du domaine kinase du recepteur du vegf

S. Emanuel, Dana L. Johnson, 2001 .

Oral coadministration of β-glucuronidase to increase exposure of extensively glucuronidated drugs that undergo enterohepatic recirculation.

J. Chen, Dana L. Johnson, J. Scicinski, 2012, Journal of pharmaceutical sciences.

A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists.

E. Opas, Z. Sui, Dana L. Johnson, 2013, Bioorganic & medicinal chemistry letters.

Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.

E. Opas, Z. Sui, Xuqing Zhang, 2011, Bioorganic & medicinal chemistry letters.

Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.

E. Opas, Z. Sui, Xuqing Zhang, 2011, Bioorganic & medicinal chemistry letters.

Piperidine-containing β-arylpropionic acids as potent antagonists of αvβ3/αvβ5 integrins

Dana L. Johnson, B. Tounge, B. Maryanoff, 2004 .

GLP-2 Receptor Agonism Ameliorates Inflammation and Gastrointestinal Stasis in Murine Postoperative Ileus

Dana L. Johnson, B. Moore, N. Peffer, 2010, Journal of Pharmacology and Experimental Therapeutics.

Discovery of Orally Efficacious Tetrahydrobenzimidazoles as TGR5 Agonists for Type 2 Diabetes.

T. Kirchner, F. Du, Z. Sui, 2017, ACS medicinal chemistry letters.

Evaluation of anti-diabetic effect and gall bladder function with 2-thio-5-thiomethyl substituted imidazoles as TGR5 receptor agonists.

T. Kirchner, F. Du, Z. Sui, 2017, Bioorganic & medicinal chemistry letters.

Discovery of Orally E ffi cacious Tetrahydrobenzimidazoles as TGR 5 Agonists for Type 2 Diabetes

T. Kirchner, F. Du, Z. Sui, 2017 .

Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis

M. D'Andrea, Dana L. Johnson, R. Galemmo, 2005, Molecular Cancer Therapeutics.

Matrix metalloproteinase-9 inhibition reduces inflammation and improves motility in murine models of postoperative ileus.

C. Manthey, Dana L. Johnson, A. Bauer, 2011, Gastroenterology.

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia

B. Tomczuk, S. Meegalla, C. Illig, 2009, Molecular Cancer Therapeutics.

The discovery of novel cyclohexylamide CCR2 antagonists.

C. Molloy, E. Opas, Z. Sui, 2011, Bioorganic & medicinal chemistry letters.

The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors.

H. Koblish, A. Maroney, Dana L. Johnson, 2006, Bioorganic & medicinal chemistry letters.

Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo

D. Parks, Tianbao Lu, J. Marugan, 2006, Molecular Cancer Therapeutics.

Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.

S. Emanuel, R. H. Gruninger, Angel R. Fuentes-Pesquera, 2005, Journal of medicinal chemistry.

(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.

Jian Li, Judith Baker, Hong-tao Lu, 2005, Journal of medicinal chemistry.

Discovery and SAR of 5-aminooctahydrocyclopentapyrrole-3a-carboxamides as potent CCR2 antagonists.

E. Opas, Z. Sui, Dana L. Johnson, 2014, Bioorganic & medicinal chemistry letters.

Discovery of a 4-Azetidinyl-1-thiazoyl-cyclohexane CCR2 Antagonist as a Development Candidate.

E. Opas, Z. Sui, Xuqing Zhang, 2012, ACS medicinal chemistry letters.

Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.

E. Opas, Z. Sui, Dana L. Johnson, 2013, Bioorganic & medicinal chemistry letters.

Shared and Unique Determinants of the Erythropoietin (EPO) Receptor Are Important for Binding EPO and EPO Mimetic Peptide*

I. Wilson, R. Thurmond, M. Goldsmith, 1999, The Journal of Biological Chemistry.

A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models

M. Batchelor, G. Bignan, M. D'Andrea, 2004, Molecular Pharmacology.

Peptide mimetics of erythropoietin are powerful probes of receptor activation mechanisms

I. Wilson, O. Livnah, E. Stura, 2002 .

A peptide mimetic of erythropoietin: Critical residues and description of a minimal functional epitope

I. Wilson, O. Livnah, W. Dower, 2002 .

Mutagenesis Studies of the Human Erythropoietin Receptor

R. H. Gruninger, L. Jolliffe, S. Middleton, 1997, The Journal of Biological Chemistry.

JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models.

Tianbao Lu, M. Cummings, Dana L. Johnson, 2008 .

Novel Monoclonal Antibody Is an Allosteric Insulin Receptor Antagonist That Induces Insulin Resistance

T. Kirchner, M. Chiu, Rupesh K. Nanjunda, 2016, Diabetes.

Small molecule inhibitors of methionine aminopeptidase type 2 (MetAP-2).

D. Ludovici, Dana L. Johnson, Rose M Tominovich, 2004, Angiogenesis.

Studies with an Orally Bioavailable αV Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats

S. Mousa, S. Bursell, A. Clermont, 2008, Journal of Pharmacology and Experimental Therapeutics.

Triazolopyridazines as tyrosine kinase

Tianbao Lu, M. Cummings, A. Maroney, 2006 .

Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.

J. Marugan, H. Koblish, I. Deckman, 2006, Biochemistry.

Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody

T. Kirchner, M. Chiu, Rupesh K. Nanjunda, 2018, Molecular metabolism.

Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation.

I. Wilson, O. Livnah, E. Stura, 1999, Science.

The discovery and SAR of cyclopenta[b]furans as inhibitors of CCR2.

T. Kirchner, Z. Sui, Dana L. Johnson, 2014, Bioorganic & medicinal chemistry letters.